Matthew J. D'Onofrio - San Diego CA, US David A. Gonyer - Cardiff CA, US Shirish A. Shah - Phoenix AZ, US Stuart J. Madden - Ellicott City MD, US
International Classification:
A61M 15/08 A61K 31/166 A61P 1/08 A61P 1/00
US Classification:
12820312, 514622
Abstract:
Nasal formulations of metoclopramide, which remain stable and/or colorless upon storage over a period of time, are provided. Also provided are methods of treating disorders treatable with metoclopramide, comprising administering the nasal solutions to patients in need thereof.
David A. Gonyer - Cardiff CA, US Shirish A. Shah - Phoenix AZ, US Stuart J. Madden - Ellicott City MD, US
Assignee:
EVOKE PHARMA, INC. - San Diego CA
International Classification:
C07C 237/44 A61M 11/02
US Classification:
12820021, 514619, 564167
Abstract:
Nasal formulations of metoclopramide, which remain stable and/or colorless upon storage over a period of time, are provided. Also provided are methods of treating disorders treatable with metoclopramide, comprising administering the nasal solutions to patients in need thereof.
Treatment Of Symptoms Associated With Female Gastroparesis
Matthew J. D'Onofrio - Solana Beach CA, US David A. Gonyer - Cardiff CA, US Marilyn R. Carlson - Encinitas CA, US
Assignee:
Evoke Pharma, Inc. - San Diego CA
International Classification:
A61K 31/166
US Classification:
514619
Abstract:
Nasal formulations of metoclopramide are administered for the treatment of symptoms associated with female gastroparesis. Also provided are methods of treating symptoms of female gastroparesis with nasal metoclopramide.
Nasal formulations of metoclopramide, which remain stable and/or colorless upon storage over a period of time, are provided. Also provided are methods of treating disorders treatable with metoclopramide, comprising administering the nasal solutions to patients in need thereof.
Nasal formulations of metoclopramide, which remain stable and/or colorless upon storage over a period of time, are provided. Also provided are methods of treating disorders treatable with metoclopramide, comprising administering the nasal solutions to patients in need thereof.
Nasal formulations of metoclopramide, which remain stable and/or colorless upon storage over a period of time, are provided. Also provided are methods of treating disorders treatable with metoclopramide, comprising administering the nasal solutions to patients in need thereof.
Nasal formulations of metoclopramide, which remain stable and/or colorless upon storage over a period of time, are provided. Also provided are methods of treating disorders treatable with metoclopramide, comprising administering the nasal solutions to patients in need thereof.